Nephrology
1 drug is in development for Focal Segmental Glomerulosclerosis.
- Companies
- 1
- Clinical trials
- 11
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Focal Segmental Glomerulosclerosis pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 4(1)
| Drug | Company |
|---|---|
| sparsentan | Travere Therapeutics, Inc. (TVTX) |
About this indication
Focal Segmental Glomerulosclerosis context
Nephrology·MeSH: Glomerulosclerosis, Focal Segmental (D005923)
Also known as: Focal Glomerulosclerosis, Focal Sclerosing Glomerulonephritides, Focal Sclerosing Glomerulonephritis
Frequently asked questions
How many drugs are in development for Focal Segmental Glomerulosclerosis?
BioSniper tracks 1 drug in development for Focal Segmental Glomerulosclerosis across 1 company.
How many clinical trials target Focal Segmental Glomerulosclerosis?
There are 11 clinical trials targeting Focal Segmental Glomerulosclerosis tracked by BioSniper.